

Hyun Young Woo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2684598/publications.pdf>

Version: 2024-02-01

33
papers

614
citations

623734

14
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

1248
citing authors

#	ARTICLE	IF	CITATIONS
1	Puncture needle with a hard plastic sheath and plastic wings minimizes repuncture attempts in ultrasound-guided paracentesis: a retrospective case-control study. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 18-23.	1.4	0
2	Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 459-459.	1.6	2
3	Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma. <i>Molecules</i> , 2021, 26, 295.	3.8	7
4	The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 544-556.	1.7	7
5	Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. <i>Gut and Liver</i> , 2021, 15, 440-450.	2.9	7
6	Primary hepatic sarcoidosis presenting with cholestatic liver disease and mimicking primary biliary cholangitis. <i>Yeungnam University Journal of Medicine</i> , 2021, , .	1.4	0
7	Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study. <i>Nutrients</i> , 2020, 12, 1429.	4.1	31
8	Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. <i>Vaccines</i> , 2020, 8, 321.	4.4	13
9	The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future. <i>Annals of Translational Medicine</i> , 2020, 8, 1617-1617.	1.7	2
10	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 352-363.	8.9	4
11	Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1954-1963.e3.	4.4	46
12	Outcome of donor biliary complications following living donor liver transplantation. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 705-715.	1.7	15
13	Effect of yttriumâ€90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 387-397.	3.4	6
14	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 35-44.	1.8	19
15	Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice. <i>PLoS ONE</i> , 2017, 12, e0187469.	2.5	6
16	A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 128-137.	8.9	24
17	Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea. <i>Journal of Korean Medical Science</i> , 2016, 31, 403.	2.5	9
18	The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis. <i>Journal of Korean Medical Science</i> , 2016, 31, 1604.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 267-271.	8.9	7
20	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 865-871.	2.8	2
21	Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 344.	8.9	28
22	Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. <i>Hepatology</i> , 2015, 61, 1809-1820.	7.3	117
23	New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 115.	8.9	41
24	Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 18.	8.9	22
25	Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 168.	8.9	4
26	A case of small hepatocellular carcinoma with an extensive lymph node metastasis at diagnosis. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 310.	8.9	6
27	Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2014, 32, 170.	1.5	19
28	Sorafenib in liver cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1059-1067.	1.8	50
29	Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. <i>The Korean Journal of Hepatology</i> , 2012, 18, 32.	1.5	14
30	A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e14566-e14566.	1.6	2
31	Clinicopathologic significance of the expression of Snail in hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2011, 17, 12.	1.5	18
32	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382.	2.3	55
33	Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 332-339.	1.5	20